2' 2'-DifluorodeoxyguanosineAlternative Names: dFdG; dFdGuo
Latest Information Update: 21 Oct 1997
At a glance
- Originator Eli Lilly
- Mechanism of Action DNA synthesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 21 Oct 1997 No-Development-Reported for Cancer in USA (Unknown route)
- 08 Jun 1995 New profile
- 08 Jun 1995 Preclinical development for Cancer in USA (Unknown route)